Douglas W Ball

Associate Professor

If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
Thyroid Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Neuroendocrine Tumors Medicine & Life Sciences
Small Cell Lung Carcinoma Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
Neoplasm DNA Medicine & Life Sciences
Pheochromocytoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2017

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

Schlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M. C., Niederle, B., Cohen, E. E. W., Wirth, L., Ali, H., Clary, D. O., Yaron, Y., Mangeshkar, M., Ball, D., Nelkin, B. & Sherman, S., Jan 1 2017, In : Annals of Oncology. 28, 11, p. 2813-2819 7 p.

Research output: Contribution to journalArticle

Survival Analysis
Confidence Intervals
Disease-Free Survival

A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer

Schlumberger, M., Jarzab, B., Cabanillas, M. E., Robinson, B., Pacini, F., Ball, D. W., McCaffrey, J., Newbold, K., Allison, R., Martins, R. G., Licitra, L. F., Shah, M. H., Bodenner, D., Elisei, R., Burmeister, L., Funahashi, Y., Ren, M., O'Brien, J. P. & Sherman, S. I., Jan 1 2016, In : Clinical Cancer Research. 22, 1, p. 44-53 10 p.

Research output: Contribution to journalArticle

Protein-Tyrosine Kinases
Confidence Intervals
Disease-Free Survival

Anaplastic thyroid carcinoma, version 2.2015

Haddad, R. I. , Lydiatt, W. M. , Ball, D. W. , Busaidy, N. L. , Byrd, D. , Callender, G. , Dickson, P. , Duh, Q. Y. , Ehya, H. , Haymart, M. , Hoh, C. , Hunt, J. P. , Iagaru, A. , Kandeel, F. , Kopp, P. , Lamonica, D. M. , McCaffrey, J. C. , Moley, J. F. , Parks, L. , Raeburn, C. D. & 10 others Ridge, J. A., Ringel, M. D., Scheri, R. P., Shah, J. P., Smallridge, R. C., Sturgeon, C., Wang, T. N., Wirth, L. J., Hoffmann, K. G. & Hughes, M., Sep 1 2015, In : JNCCN Journal of the National Comprehensive Cancer Network. 13, 9, p. 1140-1150 11 p.

Research output: Contribution to journalArticle

Thyroid Neoplasms
Practice Guidelines

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated t

Cabanillas, M. E., Schlumberger, M., Jarzab, B., Martins, R. G., Pacini, F., Robinson, B., McCaffrey, J. C., Shah, M. H., Bodenner, D. L., Topliss, D., Andresen, C., O'Brien, J. P., Ren, M., Funahashi, Y., Allison, R., Elisei, R., Newbold, K., Licitra, L. F., Sherman, S. I. & Ball, D. W., Aug 1 2015, In : Cancer. 121, 16, p. 2749-2756 8 p.

Research output: Contribution to journalArticle

Disease-Free Survival
Confidence Intervals
Thyroid Neoplasms
Vascular Endothelial Growth Factor A

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

Wilky, B. A., Rudek, M. A., Ahmed, S., Laheru, D. A., Cosgrove, D., Donehower, R. C., Nelkin, B., Ball, D., Doyle, L. A., Chen, H., Ye, X., Bigley, G., Womack, C. & Azad, N. S., Jan 6 2015, In : British Journal of Cancer. 112, 1, p. 24-31 8 p.

Research output: Contribution to journalArticle

Mitogen-Activated Protein Kinase Kinases
Maximum Tolerated Dose
Thyroid Neoplasms